Phase 2 Evidence and Impact Analysis
I'm working from the triage metadata and applying independent judgment across all 35 articles in this batch. Note: all articles are abstract-only, peer-reviewed, and carry classification_confidence = medium, which warrants conservative but not severe score penalties. No preprints are present.
Article-by-Article Scoring
Article 1 — Trastuzumab Deruxtecan (T-DXd) in HER2+ Advanced GI Cancer (PMID: 42720868) Triage score: 7 | Study design: Review (tagged as RCT — likely the underlying evidence base)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | T-DXd in gastric cancer is established; this is a synthesis/clinical guidance review, not a new discovery |
| Clinical Relevance | 7 | Directly addresses sequencing, patient selection, HER2 reassessment — high bedside utility |
| Population Reach | 5 | HER2+ gastric/GEJ cancer is a defined subgroup (~15–20% of gastric cancers globally, substantial absolute burden in Asia) |
| Implementation Speed | 6 | T-DXd already approved in several jurisdictions; review accelerates adoption of best practices |
| Evidence Strength | 6 | Synthesizes RCT data (DESTINY-Gastric trials); abstract only limits full assessment |
- Key quantitative result: Not reported in abstract; synthesizes existing RCT evidence
- External validation: Reviews published RCT data (DESTINY-Gastric02/04 likely included)
- Main limitation: Review design — no new primary data; abstract only
- Equity implications: HER2 testing access disparities between high- and low-income settings; regional implementation discussion noted as a focus
- Evidence Maturity: Validated (based on underlying RCT base)
Article 2 — Management of Soft Tissue and Visceral Leiomyosarcomas (PMID: 42720945) Triage score: 7 | Study design: Clinical trial (mislabeled; appears to be a guideline/consensus)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | LMS management is established; value is in consolidation and expert consensus |
| Clinical Relevance | 6 | JAMA Oncology publication, multidisciplinary authorship — likely high practice impact for sarcoma specialists |
| Population Reach | 4 | Rare cancer; ~2,000–3,000 new LMS cases/year in the US, higher relative to LMS community's unmet need |
| Implementation Speed | 5 | Consensus guidance can be adopted quickly in specialized centers |
| Evidence Strength | 5 | Abstract only; study design unclear; JAMA Oncology venue is high credibility |
- Key quantitative result: Not in abstract
- Main limitation: Rare disease, likely limited prospective trial data underlying recommendations
- Equity implications: Access to specialized sarcoma centers is highly unequal; guidelines may not help patients in underserved settings
- Evidence Maturity: Validated (within rare disease context)
Article 3 — Tertiary Lymphoid Structures in Pancreatic Cancer (PMID: 42722137) Triage score: 7 | Study design: Review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | TLS biology in PDAC is emerging and of active interest; review synthesizes a rapidly evolving area |
| Clinical Relevance | 4 | No direct clinical tool yet; research-stage relevance for immunotherapy pipeline |
| Population Reach | 6 | PDAC is a high-mortality cancer with ~60,000 cases/year in the US alone |
| Implementation Speed | 2 | Years away from clinical translation |
| Evidence Strength | 4 | Narrative/observational review; abstract only |
- Key quantitative result: Not available
- Main limitation: Review design; PDAC TLS research is still preclinical/translational
- Equity implications: PDAC disproportionately affects lower-income patients with worse access to cutting-edge immunotherapy
- Evidence Maturity: Exploratory
Article 4 — Second Transplantation for Relapsed Hematologic Malignancies (PMID: 42722158) Triage score: 7 | Study design: Observational cohort
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Second allo-HCT after MRD graft failure is an established but data-sparse area; adds real-world registry evidence |
| Clinical Relevance | 6 | Directly informs a genuinely difficult clinical decision point with limited guidance |
| Population Reach | 4 | Specific subgroup: relapsed post-HCT from MRD — relatively narrow |
| Implementation Speed | 5 | Retrospective data can inform immediate practice at transplant centers |
| Evidence Strength | 5 | Observational cohort from Japanese registry; inherent selection bias; abstract only |
- Key quantitative result: Not reported in abstract
- Main limitation: Observational design; no randomization; potential unmeasured confounders
- Equity implications: Access to second transplant is heavily resource-dependent; not available in most LMICs
- Evidence Maturity: Exploratory → Validated (within observational evidence standard for this indication)
Article 5 — B-cell Precursor ALL: Origins, Classification, and Therapeutic Advances (PMID: 42722166) Triage score: 7 | Study design: Review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | BCP-ALL biology and treatment landscape is well-covered; value in synthesis of recent advances (CAR-T, blinatumomab, etc.) |
| Clinical Relevance | 6 | Highly relevant for pediatric oncologists; summarizes treatment hierarchy |
| Population Reach | 6 | Most common pediatric cancer; ~3,000–4,000 cases/year in US; global relevance |
| Implementation Speed | 5 | Synthesizes approved/advancing therapies |
| Evidence Strength | 5 | Observational/review design; abstract only |
- Main limitation: Review design; no primary data
- Equity implications: High-income country cure rates (
90%) vs. LMICs (40–60%); access disparities are severe - Evidence Maturity: Validated (for established landscape summary)
Article 6 — Transformer-Based DL Model for TMZ Resistance Prediction in GBM (PMID: 42722555) Triage score: 7 | Study design: Observational cohort
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Applying transformer architectures to predict chemotherapy resistance from MRI is relatively novel |
| Clinical Relevance | 5 | Could change treatment sequencing in GBM if validated; currently pre-deployment |
| Population Reach | 5 | ~13,000 new GBM diagnoses/year in US; global burden is significant |
| Implementation Speed | 3 | Requires prospective validation, regulatory pathway, integration into radiology workflow |
| Evidence Strength | 4 | Single-center or limited cohort likely; abstract only; no external validation confirmed |
- Key quantitative result: Not in abstract
- Main limitation: Likely single-institution; no external prospective validation; abstract only
- Equity implications: AI diagnostic tools require MRI access — excluded populations in LMICs
- Evidence Maturity: Exploratory
Article 7 — AI-Assisted Detection of Fetal Intracranial Malformations (RCT) (PMID: 42722598) Triage score: 7 | Study design: RCT — self-crossover, multicentre
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Multicentre RCT of AI in real-world prenatal ultrasound practice is methodologically advanced vs. most AI imaging studies |
| Clinical Relevance | 7 | Directly tests impact on sonographer diagnostic performance in practice — clinically actionable |
| Population Reach | 7 | Prenatal screening is universal in most healthcare systems; fetal CNS malformations are a major cause of neonatal morbidity |
| Implementation Speed | 6 | RCT evidence in a ready-to-deploy setting; regulatory pathway for AI-assisted ultrasound is maturing |
| Evidence Strength | 7 | Multicentre RCT is strongest design in this batch; self-crossover reduces confounding; Lancet Digital Health venue |
- Key quantitative result: Not reported in abstract (key finding framed as a question — results likely in full text)
- External validation: Multicentre design provides internal cross-site validation
- Main limitation: Abstract-only limits full data review; China-specific sonographer training context may limit generalizability
- Equity implications: AI assistance could reduce performance disparities between high- and low-volume centers; benefits less-experienced sonographers disproportionately
- Evidence Maturity: Potentially Practice-Changing (conditional on full-text results confirming improvement)
Article 8 — Radiological Sarcopenia in PDAC — Narrative Review (PMID: 42720063) Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Sarcopenia as prognostic factor in PDAC is established; narrative review adds synthesis value |
| Clinical Relevance | 4 | Informs treatment decision-making but no new intervention tested |
| Population Reach | 5 | PDAC is high mortality; sarcopenia affects majority of advanced PDAC patients |
| Implementation Speed | 4 | Sarcopenia assessment via CT is already feasible; broader adoption is the gap |
| Evidence Strength | 3 | Narrative review; lowest design tier |
- Evidence Maturity: Exploratory
Article 9 — Glymphatic System and Alzheimer's Disease — Review (PMID: 42720212) Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Glymphatic-AD connection is an active frontier with growing literature; review captures emerging insights |
| Clinical Relevance | 4 | No direct clinical intervention yet; important mechanistic framing |
| Population Reach | 8 | Alzheimer's affects ~55M worldwide; any treatment advance has enormous reach |
| Implementation Speed | 2 | Deeply exploratory; therapeutics targeting glymphatic system are pre-clinical |
| Evidence Strength | 3 | Review/observational; abstract only |
- Equity implications: AD disproportionately affects aging populations in LMICs with inadequate dementia care infrastructure
- Evidence Maturity: Exploratory
Article 10 — ML Prediction of I-131 Response in Thyroid Cancer (PMID: 42720506) Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Four-class ML classification of RAI response is a useful incremental advance; interpretable ML adds modest novelty |
| Clinical Relevance | 5 | Directly relevant to post-op thyroid cancer management decisions |
| Population Reach | 5 | Differentiated thyroid cancer is common (~50,000 new cases/year in US) |
| Implementation Speed | 4 | Needs prospective validation before clinical deployment |
| Evidence Strength | 4 | Observational cohort; likely retrospective; abstract only |
- Evidence Maturity: Exploratory
Article 11 — Hypoalbuminemia and Mortality in Pediatric E. coli BSI (PMID: 42720514) Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Hypoalbuminemia as prognostic marker in sepsis is known; pediatric E. coli-specific framing is a useful narrowing |
| Clinical Relevance | 5 | Directly informs ICU monitoring; albumin is a universally available, low-cost lab test |
| Population Reach | 5 | Pediatric sepsis is a global killer; E. coli BSI is common in LMICs |
| Implementation Speed | 6 | Albumin monitoring is immediately implementable in any ICU setting |
| Evidence Strength | 5 | Observational cohort; retrospective likely; abstract only |
- Equity implications: Highly relevant to resource-limited settings where E. coli BSI burden is highest and early warning biomarkers are critical
- Evidence Maturity: Exploratory
Article 12 — Fractional Laser Meta-analysis for Atrophic Acne Scars (PMID: 42720808) Triage score: 6 | Mismatched to hematologic malignancies topic
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Comparative laser meta-analyses for acne scars are common; limited new insight |
| Clinical Relevance | 4 | Useful for dermatology practice; not high-stakes |
| Population Reach | 5 | Acne scarring is highly prevalent globally |
| Implementation Speed | 6 | Both laser modalities already in use; results inform existing practice |
| Evidence Strength | 5 | Systematic review/meta-analysis design is strong; heterogeneity acknowledged |
- Evidence Maturity: Exploratory (heterogeneity limits conclusions)
Article 13 — COX-2 Inhibitors in Cancer Prevention — Review (PMID: 42720875) Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | COX-2 inhibitors in cancer are long-studied; review synthesizes translational prospects |
| Clinical Relevance | 4 | Potential future application; cardiovascular safety concerns remain a barrier |
| Population Reach | 6 | Multiple cancer types; broad population relevance |
| Implementation Speed | 3 | Regulatory and safety hurdles significant |
| Evidence Strength | 3 | Narrative review |
- Evidence Maturity: Exploratory
Article 14 — Cardiometabolic Risk in Hypertensive vs. Normotensive Adults (PMID: 42721447) Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Well-established association; cross-sectional design adds limited new knowledge |
| Clinical Relevance | 4 | Reinforces known risk stratification |
| Population Reach | 7 | Hypertension is globally prevalent (~1.3B people) |
| Implementation Speed | 5 | Cross-sectional findings can inform immediate risk stratification protocols |
| Evidence Strength | 4 | Cross-sectional observational; South African context is valuable for equity but limits generalizability |
- Equity implications: South African population represented — important for underserved context; high relevance to SSA healthcare systems
- Evidence Maturity: Exploratory
Article 15 — PI-AttnGAN: Spectral Reconstruction for Cancer Diagnosis (PMID: 42721811) Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Physics-informed GAN for cross-modal spectral reconstruction is technically novel |
| Clinical Relevance | 3 | Very early stage; no clinical deployment pathway described |
| Population Reach | 5 | Broad cancer application if validated |
| Implementation Speed | 2 | Highly exploratory; significant technical and clinical translation gap |
| Evidence Strength | 3 | Observational/methods paper; abstract only |
- Evidence Maturity: Exploratory
Article 16 — Tirzepatide and Oral Progestogens — Drug Interaction Review (PMID: 42721915) Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Tirzepatide's GI motility effects on oral progestogen absorption is a genuinely underexplored drug interaction concern |
| Clinical Relevance | 6 | Tirzepatide use is rapidly expanding in midlife women; this safety signal is clinically important now |
| Population Reach | 6 | Millions of women on GLP-1/GIP agonists who also use oral hormonal therapy |
| Implementation Speed | 5 | Can inform prescribing guidance immediately, though hypothesis-generating only |
| Evidence Strength | 3 | Hypothesis-generating narrative review; no primary data |
- Equity implications: Women in settings without access to non-oral progestogen alternatives may be at greater risk
- Evidence Maturity: Exploratory
Article 17 — Astrocyte-Derived EV pTDP-43 as ALS Blood Biomarker (PMID: 42722112) Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Astrocyte-derived EV-enriched pTDP-43 as a cell-type specific blood biomarker is a meaningful advance in ALS diagnostics |
| Clinical Relevance | 6 | ALS has profound unmet need; a blood-based, astrocyte-specific biomarker could accelerate diagnosis |
| Population Reach | 4 | ALS is rare (~30,000 prevalent cases in US); but within ALS population the unmet need is extreme |
| Implementation Speed | 3 | Requires prospective validation in diverse cohorts; biomarker assay standardization needed |
| Evidence Strength | 5 | Clinical trial context; but abstract only, likely small n |
- Equity implications: Blood-based biomarkers democratize access vs. CSF-based tests; important for settings without lumbar puncture capacity
- Evidence Maturity: Exploratory → trending toward Validated (if clinical trial results are positive)
Article 18 — CAPN1 in MLL-Rearranged AML — Preclinical (PMID: 42722135) Triage score: 6 | Species: mixed (non-human model)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | CAPN1/SHP-1/MAPK axis in MLL-r AML is a novel mechanistic finding |
| Clinical Relevance | 3 | Non-human study; cannot exceed 5 on clinical relevance (cap applied) |
| Population Reach | 4 | MLL-r AML is ~5–10% of AML cases; high unmet need relative to prognosis |
| Implementation Speed | 1 | Preclinical; long translation horizon |
| Evidence Strength | 4 | Preclinical experimental; abstract only |
- Evidence Maturity: Exploratory
Article 19 — Targeting Skeletal Muscle Wasting — Review (PMID: 42722136) Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Muscle wasting therapeutics area is active; this review synthesizes emerging approaches |
| Clinical Relevance | 5 | Highly cross-cutting — applies to cancer cachexia, sarcopenia, NMD; no new trial data |
| Population Reach | 8 | Virtually universal relevance across aging, cancer, chronic disease |
| Implementation Speed | 3 | Most therapies in this space are still investigational |
| Evidence Strength | 3 | Narrative review; single author |
- Evidence Maturity: Exploratory
Article 20 — Cardiometabolic Risk and Health Disparities in Pregnancy (PMID: 42722199) Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Pregnancy as cardiometabolic risk window is established; focus on US health disparities adds equity framing |
| Clinical Relevance | 6 | High clinical utility for obstetric and primary care providers managing postpartum cardiovascular risk |
| Population Reach | 7 | ~3.6M US births/year; global maternal cardiovascular disease burden is enormous |
| Implementation Speed | 5 | Existing postpartum care visits are an implementation vehicle |
| Evidence Strength | 3 | Narrative review |
- Equity implications: Strong equity focus — addresses racial/ethnic disparities in maternal cardiometabolic disease; Black and Indigenous women disproportionately affected
- Evidence Maturity: Exploratory
Article 21 — Epidemiology of Primary Vitreoretinal Lymphoma (PMID: 42722339) Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | 20-year US epidemiological dataset on a rare tumor is genuinely useful; PVRL data are sparse |
| Clinical Relevance | 5 | Helps clinicians understand incidence trends and outcome benchmarks |
| Population Reach | 2 | Very rare tumor — relative importance high within ophthalmologic oncology community |
| Implementation Speed | 4 | Epidemiological data can inform diagnostic awareness and referral pathways |
| Evidence Strength | 5 | Observational cohort with substantial time series; abstract only |
- Evidence Maturity: Exploratory → Validated (within epidemiological context)
Article 22 — Ultrasound Molecular Imaging for Immunotherapy Response (PMID: 42722534) Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Molecular ultrasound targeting immune biomarkers for response assessment is an emerging paradigm |
| Clinical Relevance | 4 | Pre-clinical/early translational; addresses a real clinical problem (pseudoprogression) |
| Population Reach | 6 | Immunotherapy is used across many cancer types |
| Implementation Speed | 3 | Ultrasound contrast agents for molecular imaging require regulatory approval |
| Evidence Strength | 3 | Narrative review |
- Evidence Maturity: Exploratory
Article 23 — Digital Breast Tomosynthesis vs. Mammography — Meta-analysis (PMID: 42722554) Triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | DBT vs. DM is well-studied; this meta-analysis adds interval cancer incidence as a specific endpoint |
| Clinical Relevance | 7 | Directly relevant to breast screening policy decisions in population programs |
| Population Reach | 8 | Breast cancer screening programs cover tens of millions of women globally |
| Implementation Speed | 6 | DBT is available in many settings; meta-analysis evidence supports policy transition |
| Evidence Strength | 6 | Systematic review/meta-analysis is strongest non-trial design; heterogeneity is a known issue in DBT literature |
- Main limitation: Heterogeneity of screening protocols and intervals across included studies
- Equity implications: DBT costs more than DM — access disparities could widen if DBT becomes standard without reimbursement parity
- Evidence Maturity: Potentially Practice-Changing (for screening policy)
Article 24 — Non-Transvenous ICD Platforms — Review (PMID: 42720711) Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | S-ICD and EV-ICD comparison is covered in existing literature; review updates the framework |
| Clinical Relevance | 5 | Useful clinical reference for electrophysiologists choosing between platforms |
| Population Reach | 4 | SCD risk populations; large absolute number but well-covered therapeutically |
| Implementation Speed | 5 | Both devices commercially available |
| Evidence Strength | 4 | Review/observational framework; abstract only |
- Evidence Maturity: Exploratory
Article 25 — TCF12 in AML Mitochondrial Function (PMID: 42721011) Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | TCF12 role in AML OXPHOS regulation is a specific mechanistic contribution |
| Clinical Relevance | 3 | Observational/mechanistic; no direct clinical impact yet |
| Population Reach | 5 | AML is a common and lethal hematologic malignancy |
| Implementation Speed | 2 | Mechanistic study; long path to clinical application |
| Evidence Strength | 4 | Observational study; human cell line data likely; abstract only |
- Evidence Maturity: Exploratory
Article 26 — Breast Cancer Screening in Pregnant/Lactating Patients (PMID: 42721045) Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Practical review; covers established guidance in an underserved area |
| Clinical Relevance | 6 | Fills a practical gap for radiologists and obstetricians; pregnancy-associated breast cancer is underdiagnosed |
| Population Reach | 5 | Growing population due to delayed childbearing; high-risk hereditary patients specifically |
| Implementation Speed | 6 | Guidance immediately applicable to clinical practice |
| Evidence Strength | 3 | Narrative review; Radiographics is a teaching venue |
- Equity implications: Women without access to genetic risk assessment or specialized breast imaging centers are underserved
- Evidence Maturity: Exploratory
Article 27 — Healthy Working Life Expectancy — Multinational Cohort (PMID: 42721193) Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Multinational longitudinal approach to healthy working life expectancy is methodologically solid |
| Clinical Relevance | 3 | Policy-relevant but not directly clinical |
| Population Reach | 8 | Aging workforce is a global policy priority |
| Implementation Speed | 4 | Informs policy rather than clinical practice; medium adoption horizon |
| Evidence Strength | 5 | Longitudinal cohort, multicenter; abstract only |
- Evidence Maturity: Exploratory
Article 28 — Tumor Immune Microenvironment of Epithelial Ovarian Carcinoma (PMID: 42721374) Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Subtype-specific TIME profiling in EOC is clinically important for immunotherapy selection |
| Clinical Relevance | 5 | Could guide immunotherapy selection across EOC subtypes |
| Population Reach | 5 | ~21,000 new EOC cases/year in US; global burden is significant |
| Implementation Speed | 3 | Profiling tools need clinical validation |
| Evidence Strength | 4 | Observational study; abstract only |
- Evidence Maturity: Exploratory
Article 29 — Ensemble Learning of Pathology Foundation Models (PMID: 42721959) Triage score: 5 | Species: unknown
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Ensemble learning over pathology foundation models is a meaningful methodological advance; Cancer Cell is a high-impact venue |
| Clinical Relevance | 5 | Could substantially improve diagnostic accuracy across tumor types if validated |
| Population Reach | 7 | Applies across multiple solid tumors; broad cancer impact |
| Implementation Speed | 3 | Requires integration into pathology workflow; regulatory and infrastructure barriers |
| Evidence Strength | 5 | AI methodology paper; likely tested on held-out cohorts; abstract only; species unknown limits interpretation |
- Equity implications: Digitized pathology infrastructure required — excluded in most LMICs
- Evidence Maturity: Exploratory
Article 30 — Exercise Snacking for Cardiometabolic Risk — Scoping Review (PMID: 42722087) Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Exercise snacking concept is growing; scoping review adds structure |
| Clinical Relevance | 5 | Directly actionable lifestyle recommendation for cardiometabolic prevention |
| Population Reach | 8 | Sedentary populations globally; extremely broad application |
| Implementation Speed | 8 | Zero cost, no regulatory pathway needed; immediately implementable |
| Evidence Strength | 4 | Scoping review/evidence map; RCT base likely limited |
- Evidence Maturity: Exploratory
Article 31 — Plumieride for T2DM and Colitis — Animal Study (PMID: 42722239) Triage score: 5 | Species: animal
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Plumieride's dual T2DM + colitis mechanism via intestinal function is novel |
| Clinical Relevance | 2 | Animal study; cap applied — cannot exceed 5 on Clinical Relevance |
| Population Reach | 7 | T2DM and IBD are globally prevalent conditions |
| Implementation Speed | 1 | Pre-clinical animal study; 10+ years from clinical use |
| Evidence Strength | 4 | Preclinical experimental; animal model |
- Evidence Maturity: Exploratory
Article 32 — Metal-Based Epigenetic Therapeutics in Cancer — Review (PMID: 42722240) Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Metal-epigenetic drug intersection is emerging; combining mechanisms is a novel framing |
| Clinical Relevance | 3 | Pre-clinical landscape; no drugs in advanced trials for this specific niche |
| Population Reach | 6 | Epigenetic mechanisms are pan-cancer |
| Implementation Speed | 2 | Highly exploratory |
| Evidence Strength | 3 | Narrative review |
- Evidence Maturity: Exploratory
Article 33 — Mast Cells Suppress GBM via ER Stress — Preclinical (PMID: 42722280) Triage score: 5 | Species: mixed
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Mast cell tumor-suppressive role via ER stress in GBM is counterintuitive and novel |
| Clinical Relevance | 3 | Preclinical; non-human model; cap applied |
| Population Reach | 4 | GBM is relatively rare but uniformly fatal |
| Implementation Speed | 1 | Years from any clinical application |
| Evidence Strength | 4 | Preclinical experimental; mixed species |
- Evidence Maturity: Exploratory
Article 34 — Hypothalamic Inflammaging and T2DM — Review (PMID: 42722379) Triage score: 5 | Species: unknown
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Hypothalamic inflammaging as a central metabolic driver is gaining mechanistic credibility |
| Clinical Relevance | 4 | Mechanistic insight; no direct clinical tool yet |
| Population Reach | 8 | T2DM and aging — global epidemic scale |
| Implementation Speed | 2 | Requires therapeutic target development |
| Evidence Strength | 3 | Narrative review; species unknown |
- Evidence Maturity: Exploratory
Article 35 — Radiopharmaceutical + Immunotherapy in Advanced Prostate Cancer (PRINCE Trial Correlatives) (PMID: 42722442) Triage score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Tumor-intrinsic genomic correlatives of ¹⁷⁷Lu-PSMA-617 + pembrolizumab response is a high-value translational analysis |
| Clinical Relevance | 6 | Identifies biomarkers predictive of response to an approved/advanced therapy combination — actionable if validated |
| Population Reach | 6 | mCRPC is a large and growing population; PSMA therapy is rapidly expanding |
| Implementation Speed | 4 | Correlative study — needs prospective validation before clinical biomarker use |
| Evidence Strength | 5 | Based on PRINCE trial data (clinical trial correlatives); observational analysis of trial samples |
- Equity implications: PSMA-PET/CT and ¹⁷⁷Lu-PSMA-617 are expensive and geographically restricted
- Evidence Maturity: Exploratory → trending Validated